全文获取类型
收费全文 | 10188篇 |
免费 | 799篇 |
国内免费 | 81篇 |
专业分类
耳鼻咽喉 | 61篇 |
儿科学 | 217篇 |
妇产科学 | 227篇 |
基础医学 | 1704篇 |
口腔科学 | 202篇 |
临床医学 | 953篇 |
内科学 | 2343篇 |
皮肤病学 | 298篇 |
神经病学 | 1233篇 |
特种医学 | 299篇 |
外科学 | 1057篇 |
综合类 | 30篇 |
一般理论 | 5篇 |
预防医学 | 575篇 |
眼科学 | 122篇 |
药学 | 815篇 |
中国医学 | 13篇 |
肿瘤学 | 914篇 |
出版年
2024年 | 2篇 |
2023年 | 145篇 |
2022年 | 118篇 |
2021年 | 429篇 |
2020年 | 332篇 |
2019年 | 379篇 |
2018年 | 411篇 |
2017年 | 316篇 |
2016年 | 373篇 |
2015年 | 366篇 |
2014年 | 524篇 |
2013年 | 598篇 |
2012年 | 889篇 |
2011年 | 831篇 |
2010年 | 485篇 |
2009年 | 464篇 |
2008年 | 694篇 |
2007年 | 657篇 |
2006年 | 651篇 |
2005年 | 568篇 |
2004年 | 496篇 |
2003年 | 446篇 |
2002年 | 388篇 |
2001年 | 75篇 |
2000年 | 43篇 |
1999年 | 62篇 |
1998年 | 53篇 |
1997年 | 48篇 |
1996年 | 26篇 |
1995年 | 40篇 |
1994年 | 22篇 |
1993年 | 18篇 |
1992年 | 23篇 |
1991年 | 13篇 |
1990年 | 12篇 |
1989年 | 7篇 |
1988年 | 10篇 |
1987年 | 7篇 |
1986年 | 6篇 |
1985年 | 9篇 |
1984年 | 4篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1977年 | 4篇 |
1942年 | 1篇 |
1907年 | 2篇 |
1906年 | 3篇 |
1905年 | 3篇 |
1904年 | 2篇 |
1903年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Olivari Davide De Giorgio Daria Staszewsky Lidia Irene Fumagalli Francesca Boccardo Antonio Novelli Deborah Manfredi Martina Babini Giovanni Luciani Anita Ruggeri Laura Magliocca Aurora Zani Davide Danilo Masson Serge Belloli Angelo Pravettoni Davide Maiocchi Giuseppe Latini Roberto Ristagno Giuseppe 《Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy》2022,36(4):727-738
Cardiovascular Drugs and Therapy - Available animal models of acute heart failure (AHF) and their limitations are discussed herein. A novel and preclinically relevant porcine model of decompensated... 相似文献
2.
3.
Can leukocyte telomere shortening be a possible biomarker to track Huntington's disease progression?
<正>Huntington's disease(HD):HD is an autosomal dominant neurodegenerative disease,caused by a CAG trinucleotide repeat expansion in the first exon of the HTT gene encoding the huntingtin protein.The mutant protein contains an expanded polyglutamine sequence that confers a toxic gain-of-function and causes neurodegeneration.Moreover,several studies indicate that loss of the normal protein beneficial 相似文献
4.
A.V. Marzano G. Genovese G. Casazza M.T. Fierro P. Dapavo N. Crimi S. Ferrucci P. Pepe S. Liberati P.D. Pigatto A. Offidani E. Martina G. Girolomoni M. Rovaris C. Foti L. Stingeni A. Cristaudo G.W. Canonica E. Nettis R. Asero 《Journal of the European Academy of Dermatology and Venereology》2019,33(5):918-924
5.
Pietro A. Canetta Jonathan P. Troost Shannon Mahoney Amy J. Kogon Noelle Carlozzi Sharon M. Bartosh Yi Cai T. Keefe Davis Hilda Fernandez Alessia Fornoni Rasheed A. Gbadegesin Emily Herreshoff John D. Mahan Patrick H. Nachman David T. Selewski Christine B. Sethna Tarak Srivastava Katherine R. Tuttle Lisa M. Guay-Woodford 《Kidney international》2019,95(5):1209-1224
6.
Annalucia Virdi Carlotta Baraldi Alessia Barisani Barbara Corti Francesco Savoia Annalisa Patrizi Iria Neri 《Journal of cutaneous pathology》2019,46(5):389-392
Plaque‐like myofibroblastic tumor is a rare and benign pediatric soft tissue tumor. It presents as a slowly growing plaque reaching several centimeters in diameter, made up of multiple nodules. The clinical and histological features of this benign entity are similar to other fibrohistiocytic or myofibroblastic tumors occurring in childhood, so the diagnosis can be difficult. The correlation between clinical data, histopathology, and immunohistochemistry is necessary for the correct diagnosis. 相似文献
7.
Filippo Pietrantonio Christian Cotsoglou Giovanni Fucà Salvatore Lo Vullo Federico Nichetti Massimo Milione Jorgelina Coppa Marta Vaiani Alessandra Alessi Michele Prisciandaro Michele Droz-Dit Busset Federica Morano Salvatore Corallo Silvia Lazzati Maria Antista Alessia Mennitto Giovanni Randon Alessandra Raimondi Vincenzo Mazzaferro 《Clinical colorectal cancer》2019,18(1):34-43.e6
Background
In colorectal cancer liver metastases (CRCLM), bevacizumab-based neoadjuvant strategies provide increased pathologic response. We aimed at assessing the activity of perioperative capecitabine, oxaliplatin, irinotecan, and bevacizumab (COI-B regimen) in patients with potentially resectable CRCLM, and investigating biomarkers for early prediction of pathologic response.Patients and Methods
This was a single-center phase II study enrolling patients with liver-limited, borderline resectable disease and/or high-risk features. Patients received 5 preoperative and 4 postoperative cycles of biweekly COI-B (irinotecan 180 mg/m2 and bevacizumab 5 mg/Kg on day 1, oxaliplatin 85 mg/m2 on day 2, and capecitabine 1000 mg/m2 twice a day on days 2 to 6). The primary endpoint was pathologic response rate in the intention-to-treat population. A Simon 2-stage design was adopted to detect an increase from 30% to 50% with a power of 90%. Dynamic imaging biomarkers (early tumor shrinkage [ETS], deepness of response, maximum standardized uptake volume [SUVmax]/regression index) and next generation sequencing data were explored as surrogates.Results
From June 2013 to March 2017, 46 patients were enrolled. Pathologic response was achieved in 63% patients (endpoint met), and responders achieved significantly better survival outcomes with respect to non-responders. The most frequent grade 3/4 adverse events were diarrhea and neutropenia (8.7%) in the preoperative phase and thromboembolic events (5.9%) in the postoperative phase. ETS and lower SUV-2 were significantly associated with pathologic response.Conclusion
The COI-B regimen is a feasible and highly active perioperative strategy in patients with molecularly unselected, potentially resectable CRCLM. ETS and SUV-2 have a promising role as imaging-based biomarkers for pathologic response. 相似文献8.
Paolo Bossi Mario Airoldi Maria Antonietta Aloe Spiriti Andrea Antonuzzo Giorgio Bonciarelli Alessia Campagna 《Expert opinion on drug safety》2020,19(2):187-204
ABSTRACTIntroduction: A range of combination chemotherapy regimens are currently used in clinical practice. However, international antiemetic guidelines often only categorize the emetogenic potential of single agents rather than the emetogenicity of combination chemotherapy regimens. To manage the nausea and vomiting induced by antineoplastic combinations, guidelines suggest antiemetics that are appropriate for the component drug with the highest emetogenic potential. Furthermore, antiemetic guidelines generally do not consider the influence of other factors, including individual patient characteristics, on the emetic effects of cancer treatments. Similarly, the emetogenic potential of radiotherapy is stratified only according to the site of radiation, while other factors contributing to emetic risk are overlooked.Areas covered: An Expert Panel was convened to examine unresolved issues and summarize the current clinical research on managing nausea and vomiting associated with combination chemotherapy and radiotherapy.Expert opinion: The panel identified the incidence of nausea and vomiting induced by multi-drug combination therapies currently used to treat cancer at different anatomic sites and by radiotherapy in the presence of other risk factors. Based on these data and the clinical experience of panel members, several suggestions are made for a practical approach to prevent or manage nausea and vomiting due to chemotherapy regimens and radiation therapy. 相似文献
9.